Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the transaction, the insider now owns 822,255 shares of the company's stock, valued at approximately $28,778,925. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Monopar Therapeutics Trading Down 13.3 %
Shares of NASDAQ MNPR opened at $30.00 on Friday. The firm has a market capitalization of $183.39 million, a P/E ratio of -15.23 and a beta of 1.01. The firm's 50-day moving average price is $38.29 and its 200-day moving average price is $24.88. Monopar Therapeutics Inc. has a 1-year low of $1.72 and a 1-year high of $54.30.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87). Equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current year.
Institutional Trading of Monopar Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter worth $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at about $2,861,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics in the 4th quarter worth about $3,694,000. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics in the 4th quarter valued at about $11,247,000. 1.83% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently commented on MNPR. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $44.00.
Check Out Our Latest Stock Report on MNPR
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
